🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Unichem Laboratories Limited UNICHEMLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.unichemlabs.com
Company Profile ↓
₹550.20
+13.56% 1Y
Mkt Cap₹3,873.72 Cr
P/E15.35
P/B1.27
52W High₹650.60
52W Low₹284.05
Book Value₹385.97
EPS (TTM)₹35.85

Company Overview

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in Asia, Europe, Africa, CIS, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, formulations, bulk drugs, and chemicals. It serves distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 75.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 18.4% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 15.3, below the sector median of 41.6.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.18.

Recent Developments

  • Mar 2026 Revenue of ₹2,159.41 Cr (+4.6% YoY); net profit ₹252.84 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +4.6%, earnings +83.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 18.4%, profit CAGR 75.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:18.36%
1 Year:4.60%

Compounded Profit Growth

5 Years:75.01%
1 Year:83.86%

Stock Price Performance

1 Year:+13.56%
6 Months:+70.66%
3 Months:+44.92%
1 Month:+10.62%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 73% of range
₹284.05 ₹650.60
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)55.03 · Neutral
Price Performance
1M+10.62%
3M+44.92%
6M+70.66%
1Y+13.56%
Valuation vs Sector

P/E of 15.35 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 18.4% over 5 years.
  • Profit CAGR of 75.0% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
15.35
Industry PE
41.64
Forward P/E est.
8.35
PEG Ratio
-
Book Value
₹385.97
Price to Book
1.27
P/S
1.57
EV/EBITDA
20.16
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
18.36%
Profit 5Y
75.01%
Revenue (YoY)
4.60%
Earnings (YoY)
83.86%

Profitability & Returns

ROCE
11.36%
ROE
9.30%
ROA
6.77%
Profit Margin
11.71%
Op Margin
2.94%
Gross Margin
46.44%
EPS (Latest Qtr)
₹1.55
EPS (TTM)
₹35.85

Balance Sheet & Liquidity

Debt/Equity
0.18
Quick Ratio
1.38
Current Ratio
2.48
Debt
₹500.15 Cr
Total Assets
₹3,737.44 Cr
Current Assets
₹2,197.34 Cr
Working Capital
₹1,311.40 Cr

Ownership

Promoter Holding
71.26%
Chg in Prom Hold
-0.03%
FII / Inst Holding
10.19%
Chg in FII Hold
0.03%

Financial Snapshot

Enterprise Value
₹3,873.72 Cr
Total Revenue (TTM)
₹2,159.41 Cr
EBITDA
₹448.98 Cr
Free Cash Flow
₹-119.40 Cr
Operating Cash Flow
₹3.64 Cr
Shares Outstanding
₹7.04 Cr
Gross Margin
46.44%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 UNICHEMLAB Unichem Laboratories Limited NSEPHARMA 550.20 15.35 ₹3,873.72 Cr 0.00% 11.36% 9.30% 18.36% 75.01%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 402.00 Cr423.00 Cr416.00 Cr466.00 Cr432.00 Cr483.00 Cr507.00 Cr533.00 Cr587.18 Cr526.60 Cr578.96 Cr521.17 Cr575.12 Cr
Cost of Revenue --------264.57 Cr245.05 Cr270.38 Cr237.10 Cr268.02 Cr
Gross Profit --------322.61 Cr281.55 Cr308.58 Cr284.07 Cr307.10 Cr
Operating Expenses 386.00 Cr395.00 Cr407.00 Cr435.00 Cr406.00 Cr443.00 Cr452.00 Cr448.00 Cr268.60 Cr290.85 Cr273.87 Cr270.54 Cr290.03 Cr
Operating Income -14.00 Cr-1.00 Cr-20.00 Cr-1.00 Cr-2.00 Cr8.00 Cr23.00 Cr55.00 Cr54.01 Cr-9.30 Cr34.71 Cr13.53 Cr17.07 Cr
EBITDA 16.00 Cr28.00 Cr9.00 Cr31.00 Cr25.00 Cr40.00 Cr55.00 Cr86.00 Cr92.95 Cr29.31 Cr28.89 Cr332.10 Cr58.79 Cr
Interest Expense 6.00 Cr6.00 Cr7.00 Cr6.00 Cr5.00 Cr4.00 Cr5.00 Cr7.00 Cr5.46 Cr6.54 Cr8.24 Cr7.42 Cr9.39 Cr
Pretax Income -47.00 Cr2.00 Cr-22.00 Cr73.00 Cr-126.00 Cr8.00 Cr27.00 Cr62.00 Cr57.80 Cr-9.02 Cr-10.82 Cr293.43 Cr18.79 Cr
Tax Provision 2.82 Cr2.64 Cr-2.64 Cr-0-3.78 Cr5.92 Cr2.43 Cr3.72 Cr4.83 Cr1.45 Cr1.07 Cr29.14 Cr7.88 Cr
Net Income -44.00 Cr-1.00 Cr-24.00 Cr73.00 Cr-129.00 Cr2.00 Cr25.00 Cr58.00 Cr52.97 Cr-10.47 Cr-11.89 Cr264.29 Cr10.91 Cr
Diluted EPS -6.29-0.10-3.4810.40-18.370.293.508.227.50-1.49-1.6937.471.55

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,202.00 Cr1,333.00 Cr698.00 Cr815.00 Cr1,180.00 Cr1,104.00 Cr1,235.00 Cr-1,302.42 Cr1,737.63 Cr2,064.48 Cr2,159.41 Cr
Cost of Revenue --------673.17 Cr864.13 Cr995.31 Cr1,156.60 Cr
Gross Profit --------629.25 Cr873.50 Cr1,069.17 Cr1,002.81 Cr
Operating Expenses 1,100.00 Cr1,169.00 Cr738.00 Cr942.00 Cr1,254.00 Cr1,153.00 Cr1,144.00 Cr-784.83 Cr909.78 Cr928.87 Cr939.24 Cr
Operating Income 60.00 Cr125.00 Cr-85.00 Cr-179.00 Cr-141.00 Cr-131.00 Cr7.00 Cr--155.58 Cr-36.28 Cr140.30 Cr63.57 Cr
EBITDA 101.00 Cr164.00 Cr-41.00 Cr-128.00 Cr-74.00 Cr-49.00 Cr91.00 Cr--46.67 Cr60.35 Cr299.85 Cr448.98 Cr
Interest Expense 3.00 Cr3.00 Cr3.00 Cr8.00 Cr8.00 Cr8.00 Cr5.00 Cr-16.25 Cr22.15 Cr20.70 Cr31.48 Cr
Pretax Income 77.00 Cr137.00 Cr97.00 Cr2,548.00 Cr-58.00 Cr-48.00 Cr51.00 Cr--176.36 Cr-84.96 Cr154.59 Cr292.38 Cr
Tax Provision 2.31 Cr28.77 Cr-11.64 Cr034.22 Cr-12.00 Cr16.83 Cr-25.86 Cr8.80 Cr17.07 Cr39.54 Cr
Net Income 75.00 Cr108.00 Cr109.00 Cr2,545.00 Cr-24.00 Cr-60.00 Cr34.00 Cr--202.23 Cr-93.76 Cr137.52 Cr252.84 Cr
Diluted EPS 8.3111.9011.96361.82-3.38-8.554.87--28.72-13.3219.4735.85

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,153.00 Cr1,274.00 Cr1,521.00 Cr3,190.00 Cr3,142.00 Cr3,145.00 Cr3,112.00 Cr-3,193.05 Cr3,274.95 Cr3,569.40 Cr3,737.44 Cr
Current Assets --------1,588.47 Cr1,743.32 Cr2,029.47 Cr2,197.34 Cr
Cash & Equivalents --------183.75 Cr154.75 Cr89.58 Cr289.48 Cr
Inventory --------625.23 Cr736.26 Cr988.74 Cr974.97 Cr
Receivables --------588.62 Cr642.31 Cr778.81 Cr828.58 Cr
Total Liabilities --------757.74 Cr836.65 Cr1,118.81 Cr1,020.00 Cr
Current Liabilities --------639.60 Cr737.60 Cr991.97 Cr885.94 Cr
Long Term Debt --------63.65 Cr38.22 Cr60.81 Cr39.12 Cr
Total Debt 22.00 Cr36.00 Cr98.00 Cr151.00 Cr200.00 Cr206.00 Cr119.00 Cr-314.05 Cr247.52 Cr459.77 Cr500.15 Cr
Total Equity 867.00 Cr954.00 Cr1,063.00 Cr2,680.00 Cr2,620.00 Cr2,531.00 Cr2,557.00 Cr-2,435.30 Cr2,438.30 Cr2,450.59 Cr2,717.44 Cr
Shares Outstanding --------7.04 Cr7.04 Cr7.04 Cr7.04 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 78.00 Cr112.00 Cr68.00 Cr-112.00 Cr-328.00 Cr20.00 Cr33.00 Cr--85.09 Cr14.00 Cr-7.02 Cr3.64 Cr
Investing Cash Flow -52.00 Cr-85.00 Cr-132.00 Cr1,648.00 Cr-286.00 Cr-36.00 Cr-66.00 Cr-202.81 Cr50.40 Cr-241.23 Cr192.06 Cr
Financing Cash Flow -51.00 Cr-33.00 Cr59.00 Cr-881.00 Cr-2.00 Cr-62.00 Cr-121.00 Cr--81.30 Cr-106.31 Cr183.76 Cr1.86 Cr
Capital Expenditure -74.00 Cr-140.00 Cr-147.00 Cr-159.00 Cr-191.00 Cr-380.00 Cr-287.00 Cr--44.32 Cr-22.55 Cr-137.36 Cr-123.04 Cr
Free Cash Flow 4.00 Cr-28.00 Cr-79.00 Cr-271.00 Cr-519.00 Cr-360.00 Cr-254.00 Cr--129.41 Cr-8.55 Cr-144.38 Cr-119.40 Cr
Net Change in Cash -25.00 Cr-7.00 Cr-4.00 Cr655.00 Cr-616.00 Cr-78.00 Cr-154.00 Cr-36.42 Cr-41.91 Cr-64.49 Cr197.56 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------48.3%50.3%51.8%46.4%
Operating Margin % 5.0%9.4%-12.2%-22.0%-11.9%-11.9%0.6%--11.9%-2.1%6.8%2.9%
Net Margin % 6.2%8.1%15.6%312.3%-2.0%-5.4%2.8%--15.5%-5.4%6.7%11.7%
ROE % 8.7%11.3%10.3%95.0%-0.9%-2.4%1.3%--8.3%-3.8%5.6%9.3%
ROCE % ---------6.1%-1.4%5.4%2.2%

Shareholding Pattern

Insiders
71.26%
Institutions
10.19%
Public Float
35.44%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for UNICHEMLAB

Google News Wed, 04 Feb 2026

Investors in Unichem Laboratories (NSE:UNICHEMLAB) from a year ago are still down 43%, even after 12% gain this past week - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxQRFBqeEhkcnR0QmRyeVY3RUpwSGlQODNuTDNFLV9IWXItb21MYkhwcjNabnJOcExuTS0ybXlRWWtmaVpDdTFNN0hrTTdHVHpvd3d1ekd0T0ZoY09INy1CQTU4ekFNeGlFTlhjSWJXLV9WN29xYzcxQnN5S3REOFo0WEpZendEQVpkdm5KQW…

Google News Wed, 26 Aug 2026

Unichem Laboratories UNICHEMLAB Volume Spurt Clarification - Kalkine India

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPeDljWEFQbUhxYjlmM0hrSV9GWkZ4TGJuNUc3ODcxd05TWWU2STVHSzVxRFJlVFQzODN6MWxzNmlfQjlmaTVLdFRuWElUNGt2MUs4RjFMQ1FFT1Y4bFAzYzJkRHhVOUYxU1doX3JUUUNvaVBGU0tDdVNWYVdSYU5NQ3dzNURJM0lfSE9IOF…

Google News ue, 16 Jun 2026

Unichem Laboratories Holds Ground at ₹445: Support and Resistance Levels in Focus - Breakout Trade - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNUVJ1TmRoMURrNXg3MEZoSi0temNHZTd0LVZaN2pQUnFqTWNWYVhITTBCRFZlTXdzcGh4WmEybE5pOFV6WU1vREUwLUZHYjFDTTI2M1JGc2ZlTHp1azIwc3Q1emViMnZiaWlGdFNIR3Y4dmhDd2lDUDl4UVVIY2ZYM2c0SmVPaFpjWDBXS1…

Google News ue, 23 Jun 2026

Unichem Laboratories Stock Prediction 2026: Analyst Targets, Forecast and Key Levels - Univest

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE14bDVodlZ5bWZVV1pfOGdJM3FrYUhLSWV3ZG9fUDJMRDFzS0VZclVhUEx3TnpNdnlSa1VhakRhVVdGWTNnRTVVRGJvbDl2RHhuNTZta3Zmd2JLZ1dKNVdRdFJJNVNoSUw3Y2UtVzM3MGFCdm1EZHc?oc=5" target="_blank">Unichem …

Google News Mon, 29 Jun 2026

Unichem Laboratories Surges Over 5%: Technical Levels and Key Drivers to Watch - Time Weighted Price - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMnJnalNmMVlaQVBuYXU2V05FeUZrazhKc3dXY2JJMXhhUHFaVjF3ajgyOHA4OUM1dFV5TGFpRHVoUWZmUjlUa1hKajJmTEE4VW5vb0I3ZHVEX0tySnN6eFVGOUx3MTlzZy1OYU9ONkNvN2R2bmZsQWZWWHUtbXg2Q3FzNEtwcF9vdTd3VD…

Google News ue, 07 Jul 2026

UNICHEMLAB Q2 2026 Earnings: Revenue Growth of 4.31% Drives Positive Stock Reaction - Margin Compression Risk - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPNmVSbUhlMlp1ZVdtdm1HSVg2YkJyNTFNbXJRNUtyTWw4UDUtQ2pwRVZNTWRPMUdjTklUb3ZxdF9ENWgtSUFCd3ZjdDNVWnNsd29FSmVTck9mNVJIMXVPcDdxaTRNMUp5UVdqR0JfVjVabTlrUU4weEZTblh4VXV4cUNlZGJxSmV1bDFsTm…

UNICHEMLAB — Frequently Asked Questions

What is the current share price of Unichem Laboratories Limited (UNICHEMLAB)?

As of 2026-09-08 04:53 IST, Unichem Laboratories Limited (UNICHEMLAB) trades at ₹550.20 on NSE. Its 52-week range is ₹284.05 to ₹650.60.

What is the market capitalisation of UNICHEMLAB?

Unichem Laboratories Limited (UNICHEMLAB) has a market capitalisation of ₹3,873.72 Cr on NSE.

What is the P/E ratio of UNICHEMLAB?

UNICHEMLAB trades at a trailing price-to-earnings (P/E) ratio of 15.35. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.27.

What is the return on equity (ROE) of UNICHEMLAB?

UNICHEMLAB has a return on equity (ROE) of 9.30%. Its return on capital employed (ROCE) is 11.36%.

Is UNICHEMLAB a good stock to buy?

This page provides a data-driven analysis of Unichem Laboratories Limited (UNICHEMLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space